Cytosorbents (CTSO) insider: 105,600 RSUs, 136,400 options disclosed
Rhea-AI Filing Summary
Phillip P. Chan, Chief Executive Officer and director of Cytosorbents Corp (CTSO), reported equity awards and holdings on 08/08/2025. The filing shows an acquisition of 105,600 restricted stock units (RSUs) with a reported price of $0 and a grant of 136,400 stock options with a $1 exercise price and an expiration date of 08/08/2035. Following the reported transactions, the filing reports 1,382,963 shares of common stock beneficially owned. Footnotes disclose multiple prior RSU grants (2015–2024), including 48,000 unvested RSUs from April 2, 2024, and state that 1,013,363 shares are owned outright by the reporting person. The RSUs and options vest in scheduled tranches and vesting generally requires continued service.
Positive
- 105,600 RSUs acquired reported on 08/08/2025 at a reported price of $0
- 136,400 stock options granted on 08/08/2025 with a $1 exercise price and expiration 08/08/2035
- Post-transaction beneficial ownership of 1,382,963 common shares reported
Negative
- None.
Insights
TL;DR: CEO Phillip Chan received 105,600 RSUs and 136,400 options; awards include explicit vesting schedules and a 10-year option term.
The filing documents standard executive equity awards on 08/08/2025: 105,600 RSUs reported at $0 and 136,400 options with a $1 exercise price expiring 08/08/2035. Footnotes detail prior RSU grants from 2015–2024 and outstanding common stock holdings. These disclosures are routine for executive compensation cycles and provide transparent vesting mechanics that condition future ownership on continued service.
TL;DR: The transaction increases reported insider holdings to 1,382,963 shares; disclosed vesting timelines and option terms are specified in the filing.
The Form 4 confirms post-transaction beneficial ownership of 1,382,963 common shares and direct beneficial ownership of 136,400 options. The filing specifies RSU and option vesting schedules and identifies previously granted RSUs and currently owned shares (including 1,013,363 shares owned outright). For investors, the filing provides clear metrics on insider holdings and the timing of potential future share issuance upon vesting or option exercise.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 136,400 | $0.00 | -- |
| Grant/Award | Common Stock | 105,600 | $0.00 | -- |
Footnotes (1)
- These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date. Includes: (i) the following RSUs that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015; (continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 96,000 RSUs granted on April 2, 2024 and of which 48,000 remain unvested as of the date hereof; and (continued from footnote 3) (iv) 1,013,363 shares of Common Stock owned by the Reporting Person. These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
